A detailed history of Nisa Investment Advisors, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 3,882 shares of IMVT stock, worth $106,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,882
Previous 3,838 1.15%
Holding current value
$106,793
Previous $101,000 4.95%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$27.51 - $27.51 $1,210 - $1,210
44 Added 1.15%
3,882 $106,000
Q2 2024

Jul 19, 2024

BUY
$25.1 - $31.61 $1,029 - $1,296
41 Added 1.08%
3,838 $101,000
Q1 2024

May 01, 2024

BUY
$30.27 - $43.79 $1,150 - $1,664
38 Added 1.01%
3,797 $122,000
Q4 2023

Jan 25, 2024

SELL
$31.31 - $44.19 $3,131 - $4,419
-100 Reduced 2.59%
3,759 $158,000
Q2 2023

Aug 11, 2023

BUY
$14.2 - $23.75 $3,834 - $6,412
270 Added 7.52%
3,859 $73,000
Q1 2023

May 02, 2023

SELL
$15.27 - $19.72 $34,357 - $44,370
-2,250 Reduced 38.53%
3,589 $56,000
Q4 2022

Feb 02, 2023

BUY
$6.59 - $17.75 $257 - $692
39 Added 0.67%
5,839 $104,000
Q3 2022

Nov 07, 2022

BUY
$3.93 - $6.37 $3,930 - $6,370
1,000 Added 20.83%
5,800 $59,000
Q2 2022

Aug 03, 2022

BUY
$3.38 - $5.65 $14,872 - $24,860
4,400 Added 1100.0%
4,800 $19,000
Q1 2022

Apr 29, 2022

SELL
$5.06 - $8.77 $18,317 - $31,747
-3,620 Reduced 90.05%
400 $2,000
Q4 2021

Feb 03, 2022

SELL
$7.33 - $9.32 $21,110 - $26,841
-2,880 Reduced 41.74%
4,020 $28,000
Q3 2021

Oct 18, 2021

BUY
$7.01 - $11.37 $45,565 - $73,905
6,500 Added 1625.0%
6,900 $60,000
Q1 2021

Apr 26, 2021

SELL
$13.08 - $49.6 $17,004 - $64,480
-1,300 Reduced 76.47%
400 $6,000
Q4 2020

Jan 25, 2021

BUY
$36.36 - $52.71 $61,812 - $89,607
1,700 New
1,700 $79,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.